//img.uscri.be/pth/f898911fbc96d221a465c4f073d213d7ac0a7709
Cet ouvrage fait partie de la bibliothèque YouScribe
Obtenez un accès à la bibliothèque pour le lire en ligne
En savoir plus

Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets

3 pages
Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets PR Newswire MOUNTAIN VIEW, California, June 21, 2012 - Biomarker validation analyses create surge in demand for formalin- fixed, paraffin-embedded sample prep solutions MOUNTAIN VIEW, California, June 21, 2012 /PRNewswire/ -- Hundreds of millions of formalin-fixed, paraffin-embedded (FFPE) archive specimens available globally have piqued tremendous interest for biomarker validation studies, generating a surge in demand for FFPE sample prep solutions. FFPE archive specimens from patients with known clinical outcomes provide an economic and readily available source for the biomarker validation needed to develop clinical molecular cancer tests. Analysis from Frost & Sullivan's (http://www.clinicaldiagnostics.frost.com) Demand Analysis of U.S. Cancer Sample Prep Market research finds that automated sample prep systems developed specifically for FFPE provide greater sample throughput and satisfy the requirements of various end users. If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at britni.myers@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country. Archived tissues are Institutional Review Board (IRB) exempt and are a feasible alternative to validating biomarkers when compared to costly prospective clinical trials.
Voir plus Voir moins
Frost & Sullivan: Expanding Sample Prep
Market Supports Growth Trends in Molecular
Diagnostics Markets
PR Newswire
MOUNTAIN VIEW, California, June 21, 2012
- Biomarker validation analyses create surge in demand for formalin-
fixed, paraffin-embedded sample prep solutions
MOUNTAIN VIEW, California
,
June 21, 2012
/PRNewswire/ -- Hundreds of millions
of formalin-fixed, paraffin-embedded (FFPE) archive specimens available
globally have piqued tremendous interest for biomarker validation studies,
generating a surge in demand for FFPE sample prep solutions. FFPE archive
specimens from patients with known clinical outcomes provide an economic
and readily available source for the biomarker validation needed to develop
clinical molecular cancer tests.
Analysis from Frost & Sullivan's (http://www.clinicaldiagnostics.frost.com)
Demand Analysis of U.S. Cancer Sample Prep Market
research finds that
automated sample prep systems developed specifically for FFPE provide
greater sample throughput and satisfy the requirements of various end users.
If you are interested in more information on this research, please send an
email to Britni Myers, Corporate Communications, at britni.myers@frost.com,
with your full name, company name, job title, telephone number, company
email address, company website, city, state and country.
Archived tissues are Institutional Review Board (IRB) exempt and are a feasible
alternative to validating biomarkers when compared to costly prospective
clinical trials. Therefore, pharmaceutical companies and research institutes are
employing FFPE services for their pharmacogenomics programs.
"Translational research using FFPE archive specimens is helping to produce an
expanding menu of future molecular-based cancer testing," said Frost &
Sullivan Industry Analyst Winny Tan. "A Frost & Sullivan survey of molecular
pathology labs in
the United States
reveals that nucleic acid extraction from
FFPE specimens is poised for more than 20 percent volume growth in the next
three years."
Molecular sample prep vendors have offered kits for FFPE specimens for the
last three to five years. Process automation signals the brink of a market
expansion fueled by the increased throughput. Additionally, clinical molecular
tests for serine/threonine-protein kinase B-Raf (BRAF) and GTPase Kras (KRAS)
gene biomarkers, as well as for epidermal growth factor receptor (EGFR), are
driving the demand for the FFPE sample preps.
Sample prep for FFPE specimens that produce nucleic acid extractions of high
purity and yield will become even more critical for downstream molecular
testing. The clinical labs surveyed by Frost & Sullivan anticipate an inevitable
integration of molecular extraction techniques with the long FFPE legacy that
exists in solid tumor diagnostics.
However, growth of this market is hindered by the limited number of sites
where molecular pathology is performed as well as the slow adoption of FFPE
sample prep automation by hospital laboratories. Further, hospital budgets are